Return to search

Debenture Financing for Protiva Biotherapeutics

Protiva Biotherapeutics, a Seattle-based biotechnology company focused on pharmaceutical products to fight against cancer, metabolic and infectious disease, has secured convertible debenture financing to the tune of $3.3 million from GrowthWorks Capital, BDC Capital, Kinetic Capital and the Canadian Medical Discoveries Fund.